TY - JOUR
T1 - Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients
AU - Kano, Hirohisa
AU - Kubo, Toshio
AU - Ninomiya, Kiichiro
AU - Ichihara, Eiki
AU - Ohashi, Kadoaki
AU - Rai, Kammei
AU - Hotta, Katsuyuki
AU - Tabata, Masahiro
AU - Hiraki, Takao
AU - Kanazawa, Susumu
AU - Maeda, Yoshinobu
AU - Kiura, Katsuyuki
N1 - Publisher Copyright:
© 2021 The Japanese Respiratory Society
PY - 2021/3
Y1 - 2021/3
N2 - Background: New therapeutic drugs have been developed for non-small cell lung cancer (NSCLC), and the prognosis of advanced NSCLC patients has improved. However, resistance to these drugs is a concern, and re-biopsy is necessary to determine the mechanism of drug resistance. There are many reports about the protocols for re-biopsy, including techniques such as bronchoscopy and computed tomography-guided needle biopsy (CTNB); however, there is no consensus on which method is optimal. Therefore, we retrospectively reviewed the bronchoscopy and CTNB re-biopsies conducted at our hospital. Methods: We retrospectively analyzed 79 cases of re-biopsies with bronchoscopy or CTNB in patients with NSCLC from January 2014 to December 2016 at our institute. Results: Forty-nine cases of bronchoscopy and 30 cases of CTNB were taken for re-biopsy. The diagnostic rates of bronchoscopy and CTNB were 83.7% and 100%, respectively (p = 0.023). The complication rates of bronchoscopy and CTNB were 18.4% and 36.7%, respectively (p = 0.11), with a statistically significant difference in the incidence of pneumothorax (0% vs. 23.3%, respectively; p < 0.01). Pneumothorax required drainage in 6.7% of all CTNB cases. There were no fatalities in either group. Conclusions: CTNB showed a higher diagnostic rate; however, it was associated with a higher rate of complications such as pneumothorax. Hence, the optimal modality must be determined individually for each patient.
AB - Background: New therapeutic drugs have been developed for non-small cell lung cancer (NSCLC), and the prognosis of advanced NSCLC patients has improved. However, resistance to these drugs is a concern, and re-biopsy is necessary to determine the mechanism of drug resistance. There are many reports about the protocols for re-biopsy, including techniques such as bronchoscopy and computed tomography-guided needle biopsy (CTNB); however, there is no consensus on which method is optimal. Therefore, we retrospectively reviewed the bronchoscopy and CTNB re-biopsies conducted at our hospital. Methods: We retrospectively analyzed 79 cases of re-biopsies with bronchoscopy or CTNB in patients with NSCLC from January 2014 to December 2016 at our institute. Results: Forty-nine cases of bronchoscopy and 30 cases of CTNB were taken for re-biopsy. The diagnostic rates of bronchoscopy and CTNB were 83.7% and 100%, respectively (p = 0.023). The complication rates of bronchoscopy and CTNB were 18.4% and 36.7%, respectively (p = 0.11), with a statistically significant difference in the incidence of pneumothorax (0% vs. 23.3%, respectively; p < 0.01). Pneumothorax required drainage in 6.7% of all CTNB cases. There were no fatalities in either group. Conclusions: CTNB showed a higher diagnostic rate; however, it was associated with a higher rate of complications such as pneumothorax. Hence, the optimal modality must be determined individually for each patient.
KW - Bronchoscopy
KW - Computed tomography-guided needle biopsy
KW - Non-small cell lung cancer
KW - Re-biopsy
UR - http://www.scopus.com/inward/record.url?scp=85099245235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099245235&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2020.12.001
DO - 10.1016/j.resinv.2020.12.001
M3 - Article
C2 - 33436353
AN - SCOPUS:85099245235
SN - 2212-5345
VL - 59
SP - 240
EP - 246
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 2
ER -